Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Decline in Short Interest
Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Decline in Short Interest
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) saw a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 34,600 shares, a decrease of 23.3% from the July 15th total of 45,100 shares. Based on an average daily volume of 29,000 shares, the days-to-cover ratio is currently 1.2 days.
生物绿洲科技公司(BiOasis Technologies Inc.)看到，7月份空头股数的销量大幅下降。截至7月31日，空头股数共有3.46万股，比7月15日的4.51万股减少了23.3%。以日均成交量29,000股计算，目前天数与回补比率为1.2天。
Bioasis Technologies Stock Performance
BiOASIS科技股表现
Shares of OTCMKTS BIOAF opened at $0.12 on Friday. The business's 50 day moving average is $0.13 and its 200-day moving average is $0.17. Bioasis Technologies has a 1-year low of $0.10 and a 1-year high of $0.28.
上周五，OTCMKTS BIOAF的股价开盘报0.12美元。该业务的50日移动均线切入位在0.13美元，200日移动均线切入位在0.17美元。BiOasis Technologies的一年低点为0.10美元，一年高位为0.28美元。
Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last posted its earnings results on Tuesday, June 14th. The company reported ($0.01) earnings per share for the quarter. On average, sell-side analysts forecast that Bioasis Technologies will post -0.05 earnings per share for the current fiscal year.
BiOasis Technologies(OTCMKTS：BIOAF-GET Rating)最近一次公布财报是在6月14日(星期二)。该公司公布了本季度每股收益(0.01美元)。卖方分析师平均预测，BiOasis Technologies本财年每股收益将为0.05美元。
About Bioasis Technologies
关于BiOASIS技术公司
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
BiOASIS技术公司是一家处于发展阶段的生物制药公司，致力于神经疾病和障碍的诊断和治疗产品的研究和开发。它正在开发xB3，这是一种通过血脑屏障(BBB)运输治疗剂的平台技术；以及治疗中枢神经系统疾病(CNS)，包括脑癌，以及代谢和神经退行性疾病。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免费获取StockNews.com关于BiOASIS技术的研究报告(BIOAF)
- 值得关注的两场重要的零售股大战
- MarketBeat：回顾中的一周2012-8-8
- 什么是WallStreetBets，他们的目标是什么股票？
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗？
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BiOASIS技术日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对BiOasis Technologies及相关公司的评级的每日摘要。
